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To identify HLA alleles closely involved in the auto-antigen presentation in acquired aplastic anemia (AA), 
we studied the HLA allelic loss frequencies of 312 AA patients, including 43 patients with loss of 
heterozygosity of 6p chromosome (6pLOH). An analysis of the HLA alleles contained in the lost haplotype 
revealed HLA-B*40:02 to be the most frequently lost allele. When we examined 28 AA (12 6pLOH[+] and 
16 6pLOH[-]) patients with HLA-B*40:02 for the presence of leukocytes lacking HLA-B4002 (B4002[-]) 
using a new monoclonal antibody specific to this allele, B4002(-) granulocytes were detected not only in 
all 6pLOH(+) patients but also in 9 (56%) of the 16 6pLOH(-) patients. Furthermore, 10 (83%) of the 12 
6pLOH(+) patients possessed 1.0%-78% B4002(-) granulocytes that retained the HLA-A allele on the 
same haplotype (B4002[-]A[+]), suggesting the frequent co-existence of granulocytes that underwent 
mutations restricted to HLA-B*40:02 with 6pLOH(+) (B4002[-]A[-]) granulocytes. Deep sequencing of 
the HLA-B*40:02 of sorted B4002(-)A(+) granulocytes revealed various somatic mutations, such as 
frameshift, nonsense and splice site mutations, in all 15 patients studied. Surprisingly, missense mutations 
in the α-3 domain of HLA-B*40:02 that is not involved in the antigen presentation were detected 
exclusively in the B4002(+) granulocytes of three patients possessing B4002(-) granulocytes. The 
markedly high prevalence of leukocytes lacking HLA-B4002 as a result of either or both 6pLOH or 
structural gene mutations suggests that antigen presentation by hematopoietic stem/progenitor cells to 
cytotoxic T cells via the HLA-B allele plays a critical role in the pathogenesis of AA. 
 
Key Points 
1. Somatic mutations of HLA-B*40:02 are highly frequently detected in granulocyte of patients with 
acquired aplastic anemia. 




Acquired aplastic anemia (AA) is thought to be a T-cell mediated autoimmune disease based on a good 
response to immunosuppressive therapy, such as anti-thymocyte globulin (ATG) and/or cyclosporine 
(CsA).1 A large body of in vitro evidence suggests the essential role of T cells in the development of AA, 
which includes the presence of T cells with particular T-cell receptor clonotypes,2-7 cytotoxic T-cell clones 
capable of killing hematopoietic stem/progenitor cells (HSPCs),2,4 and leukocytes that lack HLA class I 
antigens due to copy-number neutral loss of heterozygosity in the short arm of chromosome 6 (6pLOH).8-12 
Among these suggestive findings, the presence of 6pLOH(+) leukocytes is considered to be the most 
compelling evidence that cytotoxic T cells (CTLs) are involved in the development of bone marrow failure, 
as it represents the escape of HSPCs with 6pLOH from the attack of CTLs that are specific to 
auto-antigens presented by the lacked HLA class I allele. However, the incidence of 6pLOH in AA patients 
shown by several studies was at most 13%, and it is therefore unclear to what extent the HSPC-specific 




We previously determined the missing frequencies of individual HLA alleles by analyzing the alleles 
contained in the missing haplotype of 6pLOH(+) AA patients and found that four alleles (HLA-A*02:01, 
A*02:06, A*31:01, and B*40:02) were significantly more likely to be lost than the other HLA alleles.9 
However, it was difficult to determine which allele in the missing haplotype was actually responsible for 
the antigen presentation because the lost fragment of chromosome 6p usually contained two or more HLA 
alleles, and allele-specific monoclonal antibodies (mAbs) useful for detecting leukocytes lacking single 
alleles were not commercially available, except for mAbs specific to some HLA-A alleles. 
Among the four HLA class I alleles, an important role of HLA-B*40:02 in auto-antigen presentation 
in AA has been suggested by other studies. A congress abstract13 reported a markedly high prevalence of 
HLA-B61, a corresponding serotype to HLA-B*40:02, in Japanese pediatric AA patients. Inaguma et al14 
established a CTL clone capable of suppressing HSPCs in a HLA-B*40:02-restricted manner from an AA 
patient who possessed HLA-B*40:02-lacking leukocytes due to 6pLOH. Osumi et al15 reported a case of 
AA whose leukocytes had a nonsense mutation in HLA-B*40:02, suggesting the presence of leukocytes 
lacking only HLA-B4002. Given these findings, a flow cytometry (FCM) analysis using 
HLA-B4002-specific mAbs may reveal leukocytes that lack HLA-B4002 due to mechanisms other than 
6pLOH in AA patients carrying HLA-B*40:02. Many researchers have tried to generate a mAb specific for 
HLA-B61 by immunizing transgenic mice, but all attempts have failed for some reason. If anti-HLA-B61 
mAbs were generated, it would greatly facilitate the understanding of the mechanisms underlying the lack 
of HLA-B4002 from leukocytes as well as of the immune mechanisms of AA. 
We recently succeeded in generating mAbs specific to HLA-B61, taking advantage of cDNA derived 
from B lymphocytes from an AA patient possessing anti-HLA-B61 antibody as a result of multiple 
transfusions.16 The mAbs successfully identified HLA-B4002-missing leukocytes not only in 6pLOH(+) 
patients but also in 6pLOH(-) patients in the majority of AA patients possessing HLA-B*40:02, and deep 
sequencing of HLA-B4002-missing granulocyte-derived DNA revealed various mutations in the structural 
gene region of HLA-B*40:02, strongly suggesting a critical role of HLA-B4002 in the auto-antigen 
presentation of AA. 
 
Patients and methods 
Subjects 
A total of 312 Japanese patients with AA (age, 15 to 90 years old, median 65 years old; 132 males and 180 
females; 115 severe AA and 197 non-severe AA) were enrolled in an observational study to determine the 
prevalence of HLA allele-lacking leukocytes (HLA-LLs) between 2011 and 2014 (supplemental Figure 
1). The patients’ blood samples were subjected to HLA typing and droplet digital polymerase chain 
reaction (ddPCR) for detecting 6pLOH. Severe AA was diagnosed when at least two of the following 
criteria were met; the neutrophil count was < 0.5 × 109/L, the platelet count was < 20 × 109/L and the 
reticulocyte count was < 20 × 109/L.17 Very severe AA was defined as a neutrophil count < 0.2 × 109/L in 
addition to the criteria for severe AA.18 The response criteria were as previously described.19 All patients 
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were genotyped for HLA-A, HLA-B, HLA-C, and HLA-DRB1 alleles using the polymerase chain reaction 
(PCR) sequence-specific oligonucleotide method.20 All patients provided their informed consent to the 
HLA-typing and genetic analyses. The study protocols were approved by the ethical committee of 
Kanazawa University Institute of Medical, Pharmaceutical and Health Sciences. 
 
Preparation of anti-HLA-B61 antibody 
We developed a new method for generating human mAbs specific to HLA alleles by taking advantage of B 
cells from patients who had anti-HLA antibodies following repeated transfusions.16 Briefly, mononuclear 
cells isolated from 20 ml of peripheral blood from an anti-HLA-B61 antibody-positive patient were 
stimulated to differentiate into antibody-producing cells with a cytokine cocktail containing R848, 
CpG2006, anti-CD40, recombinant human interleukin (hIL)-2, hIL-4, hIL-17, hIL-21 and human B-cell 
activating factor in RPMI1640 containing 10% fetal calf serum for 6 days. CD138+ antibody-producing 
cells were then isolated with anti-CD138 antibody-conjugated microbeads using AutoMACS Pro Separator 
(Miltenyi Biotec, Bergisch Gladbach, Germany). Anti-HLA-B61 IgG antibody-producing cells were 
isolated using a microwell array chip coated with purified HLA-B61 proteins and subjected to RNA 
extraction from single cells as previously described.21,22 The antibody cDNA fragments for heavy and light 
chain variable domain fragments were amplified using the single-cell 5’-RACE method and inserted into 
expression vectors. Thereafter, HEK293 cells were transfected with the heavy and light chain vectors and 
cultured to obtain a supernatant containing complete mAb molecules. The specificity of the mAbs was 
tested by ELISA and FCM. To prevent nonspecific binding of human IgG to human Fc receptors, the Fc 
portion of the anti-HLA-B61 mAb was replaced with the constant domain of mouse IgG1. 
 
Detection of HLA-LLs and cell sorting 
HLA-LLs were detected using FACS Canto II (BD Biosciences, San Jose, USA) and analyzed with the 
FlowJo v10.1 software program (Tree star, Ashland, USA). Leukocytes lacking HLA-B4002 were referred 
to as B4002(-) cells, including both 6pLOH(+) leukocytes that lack both HLA-B4002 and one HLA-A 
allele on the same haplotype (B4002[-]A[-]) and leukocytes lacking only HLA-B4002 (B4002[-]A[+]). 
B4002(-)A(+) granulocytes and HLA-B4002-positive (B4002[+]) granulocytes and/or B4002(+) T cells 
were sorted using FACS Aria Fusion (BD Biosciences). The mAbs used for this study are provided in 
supplemental Table 1. 
 
ddPCR to detect 6pLOH involving HLA genes 
The presence of 6pLOH(+) leukocytes and their percentages of total leukocytes were determined with 
ddPCR using a QX200 AutoDG Droplet Digital PCR System (Bio-Rad, Hercules, USA) by comparing the 
copy number of each HLA allele in individuals heterozygous for the HLA allele. 6pLOH that involves 
HLA genes gives rise to a copy number imbalance between the two different alleles. The reaction mixtures 
of ddPCR included 2 TaqMan probes labeled with different fluorochromes (6-FAM or VIC) 
complementary to the allele-specific sequences, 2 primers complementary to consensus sequences 
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surrounding the allele-specific sequence, and 40 ng of genomic DNA in 1x ddPCR Supermix for Probes 
(No dUTP; Bio-Rad). We designed four primer and probe mixture that can detect 6pLOH involving HLA-A 
(A31/33 mixture), HLA-B (B1 and B2 mixture) and HLA-C (C3 mixture, supplemental Tables 2 and 3). 
The detailed protocols for ddPCR were shown in supplemental methods. 
When the lacked alleles contained in the haplotype of 6pLOH(+) patients could not be completely 
determined by ddPCR or FCM, they were estimated using a haplotype database of the Japanese population 
including 18,604 individuals from 5,824 families.23 An allele was judged to be missing as a result of 
6pLOH if the presence of the allele in the lost haplotype was estimated with >95% accuracy. 
 
Detection of HLA-B gene mutations 
To identify the somatic mutations of HLA-B*40:02 in B4002(-)A(+) granulocytes, target sequencing of 
HLA-B in sorted B4002(-)A(+) granulocytes was performed using a next-generation sequencer (NGS, 
MiSeq; Illumina, San Diego, USA). B4002(+) granulocytes and/or B4002(+) T cells from identical 
individuals were used as a control. HLA genes were enriched from genomic DNA using sequence capture 
(SeqCap EZ system; Roche Sequencing, Pleasanton, USA), a hybridization-based gene enrichment method. 
Potential mutations responsible for missing HLA-B4002 were identified when variant reads were found 
only in B4002(-) granulocytes. All of the mutations were validated using deep sequencing of HLA-B 
locus-specific long-range PCR, as previously described.24 HLA-B alleles carrying those mutations were 
determined using the nearest allele-specific SNPs. Reference sequences of HLA-B*40:02 were obtained 
from the IPD-IGMT/HLA database.25 
 
Statistical analyses 
The clinical parameters of the patients were compared using Fisher’s exact test for categorical variables 
and the Mann-Whitney U test for continuous variables with the EZR software package, a graphical user 
interface for R (The R Foundation for Statistical Computing version 2.13.0).26 
 
Results 
Allelic frequency of HLA-genes in this study subjects 
When the allelic frequency of HLA genes in 312 AA patients genotyped in this study was compared with 
those in the Japanese general population,23 HLA-B*40:02 was the fifth-most frequent allele observed in AA 
patients; the top five alleles were HLA-DRB1*15:02 (22% vs. 11%, OR=2.3, P=3.0×10-15), B*52:01 (19% 
vs. 11%, OR=1.9, P=6.0×10-9), DRB1*15:01 (14% vs. 7.7%, OR=2.0, P=4.5×10-8), C*12:02 (19% vs. 
11%, OR=1.9, P=2.8×10-8), and B*40:02 (13% vs. 7.9%, OR=1.8, P=9.3×10-6). 
 
Validation of the 6pLOH(+) cell measurement using ddPCR  
The ddPCR generated 18,745±1,553 (mean±2SD) droplets per one reaction mixture, which allowed us to 
detect at least 3%-4% 6pLOH(+) leukocytes with a specificity of 99%. The specificity of the ddPCR in 
detecting 6pLOH(+) leukocytes was verified by showing negativity for 50 healthy volunteers or AA 
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patients who were known to be negative for HLA-A-allele lacking leukocytes using FCM. To determine 
the reliability of estimating the 6pLOH(+) cell percentage by ddPCR, leukocytes from an individual 
carrying HLA-A2 and Cw3 were mixed with leukocytes from an individual not carrying A2 or Cw3 at 
various ratios, and the mixed leukocyte populations were examined by FCM and ddPCR. The percentages 
of 6pLOH(+) cells estimated by ddPCR were almost identical to those determined by FCM, suggesting 
sufficient reliability of ddPCR in measuring the percentage of 6pLOH(+) cells in the total leukocyte 
populations (supplemental Figure 2). 
 
Detection of 6pLOH and the frequency of HLA alleles involved in the lost haplotype  
Using either of the four different ddPCR mixtures, the presence of 6pLOH was evaluable in 224 (72%) of 
312 patients with AA because they were available for ddPCR in at least 1 of the 3 HLA class I loci. 
6pLOH(+) leukocytes that accounted for 3.9% to 84% (median, 10%) of the total leukocytes were detected 
in 43 (19%) of the 224 patients analyzed by the ddPCR. 6pLOH(+) patients had significantly more severe 
disease (51%) than 6pLOH(-) patients (33%, P=0.03), while age (P=0.27), sex (P=0.39) and prior 
immunosuppressive therapy (IST, P=0.44) did not differ markedly between the two groups (Table 1). 
When the prevalence of 6pLOH was compared between patients carrying and not carrying each 
HLA-allele, including alleles in HLA-A, HLA-B, HLA-C and HLA-DRB1 loci, consistent with a previous 
report,9 HLA-B*40:02 was most strongly involved in 6pLOH (34% [25/74], odds ratio [OR]=3.7, 
P=0.0002), followed by HLA-DRB1*08:02 (40% [8/20], OR=3.2, P=0.03). Of note, the HLA-B*40:02 
allele was included in the lost haplotype in all 25 6pLOH(+) patients possessing this allele. Seven of the 8 
patients with HLA-DRB1*08:02 alleles possessed HLA-B*40:02 in the same lost haplotype, while the 
remaining patient had HLA-DRB1*08:02 in the retained haplotype, suggesting that the higher frequency of 
HLA-DRB1*08:02 in 6pLOH(+) patients is due to the linkage disequilibrium between HLA-B*40:02 and 
DRB1*08:02. 
Among 150 HLA-B*40:02-negative patients, 6pLOH was detected in 18 (12%) patients. HLA-alleles 
that were more likely to be possessed by 6pLOH(+) patients were HLA-DRB1*15:01 (23% [9/40], OR=3.3, 
P=0.02), C*01:02 (24% [8/34], OR=3.3, P=0.03) and B*54:01 (29% [5/17], OR=3.8, P=0.03). 
HLA-B*54:01 was missing in all five 6pLOH(+) patients carrying this allele, while 7 of 9 
HLA-DRB1*15:01 and 2 of 8 C*01:02 in the 6pLOH(+) patients were in the retained haplotype. Three 
HLA alleles (HLA-A*02:01, A*02:06 and A*31:01) that had been suggested to be frequently lost due to 
6pLOH by our previous study9 were not significantly associated with 6pLOH in this study cohort; each 
allele was found at similar frequencies between 6pLOH(+) and 6pLOH(-) patients (HLA-A*02:01, 20% 
[11/54], OR=1.1, P=0.84; A*02:06, 13% [7/52], OR=0.59, P=0.32; and A*31:01, 16% [8/51], OR=0.73, 
P=0.55). The trend was consistent in HLA-B*40:02-negative patients (HLA-A*02:01, 11% [4/35], 
OR=0.93, P=1.0; A*02:06, 14% [5/37], OR=1.2, P=0.77; and A*31:01, 7.5% [3/38], OR=0.55, P=0.56). 
 
B4002(-) granulocytes in patients with HLA-B*40:02 
Peripheral blood samples were available for FCM using the anti-HLA-B61 antibody in 28 patients with AA 
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carrying HLA-B*40:02, including 12 6pLOH(+) and 16 6pLOH(-) patients. B4002(-) granulocytes that 
accounted for 24%-99% of the total granulocytes were detected in all of the 12 6pLOH(+) patients. 
Unexpectedly, 1.0%-99% B4002(-) granulocytes were also detected in nine (56%) of the 16 6pLOH(-) 
patients. None of 12 individuals carrying HLA-B*40:02 (6 healthy individuals and 6 patients with 
hematological malignancies) were positive for B4002(-) granulocytes. The 21 patients possessing B4002(-) 
granulocytes had more severe disease (67%, 14/21), while only 1 of the 7 patients (14%, P=0.03) not 
possessing B4002(-) granulocytes had severe disease.  
Since 10 of the 12 6pLOH(+) patients were heterozygous for the HLA-A allele, the HLA-A allelic 
expression by their B4002(-) granulocytes was able to be evaluated. As shown in Figure 1 and Table 2, 
8.0%-99% granulocytes of all the 10 6pLOH(+) patients lacked both HLA-B4002 and the HLA-A allele 
(B4002[-]A[-]) on the same haplotype containing HLA-B*40:02 and were therefore thought to represent 
6pLOH(+) granulocytes. In contrast, 8 of the 10 patients also had 1.0%-78% granulocytes that lacked 
HLA-B4002 but retained the HLA-A allele (B4002[-]A[+]), indicating that these B4002(-) cells lacked 
HLA-B4002 via mechanisms other than 6pLOH.  
Two 6pLOH(+) patients (Cases 16 and 18) were homozygous for HLA-A allele, and the percentage 
of 6pLOH(+) granulocytes was estimated using ddPCR. Only 9% and 66% of the sorted B4002(-) 
granulocytes were 6pLOH(+), suggesting that these patients also had B4002(-)A(+) granulocytes that 
accounted for 91% and 34% of B4002(-) granulocytes. None of the 20 (10 6pLOH[+] and 10 6pLOH[-]) 
patients with HLA-B*40:02 had granulocytes that lacked an HLA-A allele but retained HLA-B4002. The 
prevalence of missing HLA-B4002 from granulocytes in the 28 patients was 75% (21/28, 9 with 
B4002[-]A[+] cells alone, 10 with both B4002[-]A[+] and B4002[-]A[-] [6pLOH] cells, and 2 with 
B4002[-]A[-] cells alone, Figure 1).  
 
Mutations of HLA-B alleles in B4002(-)A(+) granulocytes 
B4002(-)A(+) granulocytes were available for mutation analyses of HLA-B alleles in 15 of the 19 patients 
who possessed the aberrant granulocytes. The mean coverage of the HLA-B gene was 426× for the capture 
method and 32,077× for the PCR method. Somatic mutations were judged to be present when the 
frequency exceeded 0.01. In total, 59 different somatic mutations of HLA-B were identified in the sorted 
B4002(-)A(+) granulocytes, all of which were present in HLA-B*40:02 and not in any of the other HLA-B 
alleles. The median variant allele frequency (VAF) was 3.7% (range, 1.0%-47%), and the number of 
mutations in each patient ranged from 1 to 9 (median 4, Figure 2 and supplemental Table 4).  
Fifty-five mutations were exonic, and four were intronic. The exonic mutations were frameshift 
duplications (n=12), frameshift deletions (n=23), an inframe deletion (n=1), nonsense mutations (n=14), a 
missense mutation (n=1), and start losses (n=4). All exonic mutations were expected to result in a lack of 
HLA-B4002 expression except for one missense mutation in Case 19, which could potentially lead to a 
structural change in the epitope recognized by anti-HLA-B61 mAb. All four intronic mutations were 
considered to be splice site mutations; two mutations deactivated 5' or 3' splice sites, whereas the other two 
were single-base substitutions within intron 3, creating alternative 5' splicing sites with a strong consensus 
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sequence, GTGAGT: TTCCTGAGT> TTCGTGAGT (c.619+133C>G) in Case 6 and GGCATGAGT> 
GGCGTGAGT (c.619+123A>G) in Case 15. The presence of alternative splice sites potentially inhibits 
normal splicing, leading to a decreased expression of HLA-B*40:02. The presence of alternatively spliced 
mRNA solely in B4002(-)A(+) granulocytes was confirmed in Case 6, whose cDNA of both sorted 
B4002(-)A(+) and B4002(+) granulocytes was available using a PCR specific for alternatively spliced 
transcripts (Figure 3). 
 
Missense mutations in the HLA-B*40:02 allele of B4002(+) granulocytes 
B4002(+) granulocytes were subjected to deep sequencing of HLA-B as a negative control in 14 of the 15 
patients possessing B4002(-)A(+) granulocytes. Surprisingly, four different missense mutations of 
HLA-B*40:02, which are not involved in the antigen presentation by this class I allele, were detected in 
B4002(+) granulocytes from 3 (Cases 3, 7, and 17) of the 14 patients (Figure 2). The same mutations were 
not detected in the corresponding B4002(-)A(+) granulocytes of all the three patients, B4002(+) T cells of 
two patients (Cases 7 and 17) or the reference sequence of HLA-B*40:02. The VAFs of the 4 missense 
mutations were 9.5% (Case 17), 9.6% (Case 17), 43% (Case 7), and 47% (Case 3), respectively. The 4 
missense mutations in B4002(+) cells and 1 missense mutation in B4002(-)A(+) cells occurred close 
together at an α-3 domain region in the protein 3-D structure (supplemental Figure 3), suggesting the 
inability of the mutant HSPCs to interact with CTLs.  
The presence of mutations in the α-3 domain region of HLA-B*40:02 in B4002(+) granulocytes of 
three patients possessing B4002(-)A(+) granulocytes prompted us to study five AA patients with 
HLA-B*40:02 who were negative for B4002(-)A(+) granulocytes. The B4002(+) granulocytes from four 
patients (Cases 23, 24, 25, and 26) without B4002(-) granulocytes and one patient (Case 1) with 6pLOH(+) 
granulocytes were subjected to deep sequencing using T cells as a negative control. No mutations were 
found in the five patients’ samples. 
 
Response to IST in patients carrying HLA-B*40:02 
Of the 28 patients carrying HLA-B*40:02, 15 patients were treated with ATG plus CsA therapy before 
(n=13) or after (n=2) sampling for the study (Table 2). All 11 (100%) patients possessing B4002(-) 
granulocytes showed a good response (complete response [CR] in 5 and partial response [PR] in 6), while 
3 of the 4 (75%) patients not possessing B4002(-) granulocytes responded (CR in 2 and PR in 1). Eleven 
patients were treated with CsA monotherapy before (n=10) and after (n=1) sampling; 7 of the 9 patients 
possessing B4002(-) granulocytes showed a response (CR in 3 and PR in 4); 1 of 2 patients not possessing 
B4002(-) granulocytes showed a response (CR). Two patients (one with B4002[-] cells and the other 
without B4002[-] cells) were not treated with IST. 
 
Chronological analysis of B4002(-) granulocytes 
The percentages of B4002(-) granulocytes in two patients (Cases 16 and 20) were determined several times 
after ATG/CsA therapy. Both patients responded to ATG therapy, and their hematological recovery was 
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associated with a decrease in the B4002(-) granulocyte percentage (83% to 4.3% and 73% to 33% after 13 
and 12 months of the therapy, respectively; Figure 4). In contrast, the B4002(-) granulocyte percentages of 
four patients (Cases 2, 3, 6 and 19) whose first samples were tested after the recovery of hematopoiesis 
following 6.2 to 23 years of ATG/CsA therapy did not change markedly when their second samples were 
examined 6 to 10 months (median, 9 months) after the first examination; 99% to 98%; 60% to 59%; 10% 
to 10%; and 79% to 85%, respectively. 
 
Discussion 
The current study in a large number of AA patients using a novel ddPCR, similar to our previous studies, 
detected 6pLOH in 19% of the patients and confirmed a significantly higher frequency of lacking 
HLA-B*40:02 than of lacking other HLA class I alleles, including HLA- A*02:01, A*02:06 and A*31:01. 
Furthermore, a new mAb specific to HLA-B61 revealed the presence of B4002(-) granulocytes in 75% of 
patients carrying HLA-B*40:02. These findings suggest that HLA-B*40:02 is critically involved in the 
auto-antigen presentation to T cells in patients with AA. The prevalence of HLA-LLs may have been 
underestimated due to a lack of mAbs specific to many other HLA alleles. 
6pLOH has been considered to be the sole or a major method of lacking class I HLAs in HSPCs 
targeted by CTLs of AA9,10,12 and in acute myeloid leukemia cells relapsed after HLA-mismatched 
hematopoietic stem cell transplantation,27,28 although some reports have shown a possible lack of HLA 
alleles due to structural gene mutations.15,29,30 Our deep sequencing in the present study of HLA class I 
genes derived from sorted B4002(-)A(+) granulocytes revealed various mutations solely in the 
HLA-B*40:02 gene. The HLA-B*40:02 mutations are apparently somatic because B4002(+)A(+) 
leukocytes were present in all patients possessing B4002(-) granulocytes and neither the B4002(+)A(+) 
granulocytes nor B4002(+) T lymphocytes from each individual showed the same mutations. The high 
number of mutations per patient with B4002(-) granulocytes (median 4) suggests that HSPC clones with 
various mutations arose in the bone marrow of the patients prior to the AA development and might have 
been selected to contribute to hematopoiesis under strong pressure by CTLs specific to auto-antigens 
presented by HLA-B4002 at the onset of AA (Figure 5). 
Recent studies using NGS have revealed clonal hematopoiesis with various somatic mutations in the 
granulocytes of AA patients, but they failed to show somatic mutations in HLA genes except for 6pLOH, 
which was detected in 13% of patients.10,31 This is mainly due to insufficient depth of the previous analyses, 
which did not focus on HLA gene regions. The somatic mutations in HLA genes do not imply a propensity 
toward myelodysplastic syndrome but may instead represent the selection by immune pressure, like PIGA 
mutations. The decrease in the B4002(-) granulocyte percentage associated with successful ATG therapy 
in two patients and the higher prevalence of B4002(-) granulocytes in severe AA than in non-severe AA 
patients support this hypothesis. 
One unexpected and important finding of this study is that B4002(+) granulocytes from three patients 
with B4002(-) granulocytes also had missense mutations in the limited α-3 domain region of HLA-B*40:02, 
which is not involved in the antigen presentation by this class I allele. CTLs require binding of their CD8 
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molecules to the α-3 domain of HLA class I to exert their function.32 The single amino acid change in the 
α-3 domain observed in the three patients may have made the mutant HSPCs resistant to the attack by 
CTLs.33,34 These findings also suggest that detecting HLA protein expression with specific mAbs may not 
be enough to screen HSPCs or leukemic cells that evade CTL attack; deep sequencing of HLA genes 
including the α-3 domain coding region is necessary. 
The allelic frequency of HLA-B*40:02 in healthy individuals is reported to be higher in Asian 
populations, with rates of 7.9% in Japanese, 8.7% in South Korean, 2.0% in Chinese, 2.4% in Thai, and 
7.7% in American Filipino populations, compared with rates of 1.6% in German, 0.3% in Northern Irish, 
1.8% in Italian, 0.9% in Swiss, and 1.5% in USA Caucasian populations.35 The higher frequency of this 
class I allele may partly explain the higher incidence of AA in Asian countries than in Western countries. 
Although the incidence of AA in the USA is much lower than in Japan, a study of 11 American AA patients 
with somatic HLA loss by Babushok et al36 also revealed that the most frequently affected allele was 
HLA-B*40:02, suggesting that an auto-antigen presented by this HLA-B is commonly involved in the 
development of AA in Japan and the USA. 
The markedly high prevalence of allele-lacking granulocytes in AA patients carrying HLA-B*40:02 
suggests that antigens presented by HLA-B4002 may serve as auto-antigens eliciting T-cell responses to 
HSPCs. We previously isolated a T-cell clone from a 6pLOH(+) patient that was capable of inhibiting 
HSPCs in a HLA-B*40:02-restricted manner but failed to identify target antigens on HSPCs due to the 
inability to propagate the T-cell clone.14 Current technology has enabled the preparation of T-cell receptor 
vectors and their transfectants by taking advantage of predominantly expanding T-cell clones in patients’ 
bone marrow in response to unknown antigens.37 Studying T cells from AA patients possessing B4002(-) 
granulocytes is therefore warranted to identify auto-antigens of AA. 
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Table 1. Comparison between 6pLOH(+) and 6pLOH(-) patients 
  
6pLOH(+) 6pLOH(-) P 
Number of patients 43 181 
 
     Age, median years (range) 69 (18-82) 64 (15-90) .27 
     Sex Male 21 73 .39 
 
Female 22 108 
 
     Severity Severe 22 60 .03 
 
Nonsevere 21 121 
 
     Prior IST ATG/CsA 5 12 .44 
 CsA 6 22  
 None 32 147  
     
HLA-B*40:02 (+) 25 49 .0002 
 
(-) 18 132 
 
     HLA-DRB1*08:02 (+) 8 12 .03 
 
(-) 35 169 
 
     HLA-A*02:01 (+) 11 43 .84 
 
(-) 32 138 
 
     HLA-A*02:06 (+) 7 45 .32 
 
(-) 36 136 
 
     HLA-A*31:01 (+) 8 43 .55 

















% of B4002(-) granulocytes Phenotype of of B4002(-) 
granulocytes 6pLOH B4002(-)A(+) 
1 68 M Nonsevere After 17 CsA CR 24% 0% 6pLOH 
2 59 M Severe After 6.2 ATG/CsA CR 99% 0% 6pLOH 
3 41 M Severe After 17 ATG/CsA CR 0% 60% B4002(-)A(+) 
4 72 M Very severe After 2.3 ATG/CsA PR 0% 2% B4002(-)A(+) 
5 30 M Severe After 1.9 ATG/CsA PR 0% 8% B4002(-)A(+) 
6 87 F Severe After 23 ATG/CsA CR 0% 10% B4002(-)A(+) 
7 15 M Severe After 3.7 ATG/CsA PR 0% 53% B4002(-)A(+) 
8 57 F Severe After 2.5 ATG/CsA PR 0% 1% B4002(-)A(+) 
9 54 F Nonsevere After 14 CsA PR 0% 99% B4002(-)A(+) 
10 56 F Nonsevere After 0.4 CsA NR 0% 70% B4002(-)A(+) 
11 57 M Severe After 1.9 CsA PR 0% 3% B4002(-)A(+) 
12 74 F Nonsevere After 25 CsA CR 13% 15% B4002(-)A(+) and 6pLOH 
13 69 F Nonsevere After 6.4 CsA PR 97% 3% B4002(-)A(+) and 6pLOH 
14 49 F Severe After 0.6 ATG/CsA PR 43% 1% B4002(-)A(+) and 6pLOH 
15 79 F Nonsevere After 1.5 CsA CR 17% 17% B4002(-)A(+) and 6pLOH 
16 21 F Very severe Before NA ATG/CsA CR 8% 75% B4002(-)A(+) and 6pLOH 
17 38 M Nonsevere After 2.2 CsA PR 36% 58% B4002(-)A(+) and 6pLOH 
18 81 F Severe Before NA No IST NA 67% 33% B4002(-)A(+) and 6pLOH 
19 28 M Very severe After 14 ATG/CsA CR 39% 40% B4002(-)A(+) and 6pLOH 
20 32 M Very severe Before NA ATG/CsA PR 21% 52% B4002(-)A(+) and 6pLOH 
21 81 M Severe Before NA CsA NR 19% 25% B4002(-)A(+) and 6pLOH 
22 66 F Nonsevere After 8.1 ATG/CsA CR 0% 0% None 
23 68 M Nonsevere After 1.7 CsA CR 0% 0% None 
24 25 M Nonsevere After 0.6 ATG/CsA NR 0% 0% None 
25 39 M Severe After 2.8 ATG/CsA CR 0% 0% None 
26 71 F Nonsevere After 1.4 ATG/CsA PR 0% 0% None 
27 24 F Nonsevere After 2.2 CsA NR 0% 0% None 
28 56 M Nonsevere Before NA No IST NA 0% 0% None 
M indicates male; F, female; CR, complete response; PR, partial response; NR, no response; B4002(-) granulocytes, granulocytes that lost B4002 






Figure 1. Detection of HLA-B4002-lacking granulocytes using an anti-HLA-B61-mAb in AA patients 
with HLA-B*40:02. (A) Representative dot plots of three patients with HLA-A2, A24 and B4002 are 
shown. (Ai) Case 22 that had only wild-type, B4002(+)A24(+)A2(+) cells. (Aii) Case 12 that showed 
B4002(-) cells that lacked HLA-B4002 but retained the both HLA-A alleles (A24 and A2) designated as 
B4002(-)A24(+)A2(+), in addition to 6pLOH(+) cells lacking both HLA-B4002 and A24 on the same 
haplotype. (Aiii) Case 7 that showed B4002(-)A24(+)A2(+) cells but did not show either B4002(-)A24(-) 
or B4002(-)A2(-) (6pLOH[+]) cells. (B) Four different patterns of HLA-B4002-lacking cell status and their 
proportions in 28 AA patients with HLA-B*40:02. 
 
Figure 2. Somatic mutations of HLA-B*40:02 in 15 patients with AA. (A) The kinds and VAFs of 
somatic mutation in individual patients identified in B4002(-)A(+) (upper graph) and B4002(+)A(+) (lower 
graph) granulocytes are shown. The kinds of mutations are designated in different colors. (B) The positions 
of all somatic mutations in the HLA-B*40:02 region are shown. The color and shape of each symbol 
correspond to those of panel A. 
 
Figure 3. A mutation creating an alternative splice site in Case 6. (A) Normal splicing of HLA-B*40:02. 
(B) The C>G mutation in intron 3 created an alternative 5' splicing site with a strong consensus sequence, 
GTGAGT, which can change the splicing of HLA-B*40:02, leading to a stop codon formation. (C) mRNA 
from three different leukocyte subsets was reversed-transcribed and amplified with alternatively spliced 
mRNA-specific primers. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA was amplified as 
an internal control. (D) The expression level of HLA-B4002 by B4002(-)A(+) granulocytes of Case 6 (Di) 
was higher than that by B4002(-)A(+) granulocytes of Case 12 (Dii) that lost HLA-B4002 due to nonsense 
and frameshift mutations. 
 
Figure 4. Chronological analysis of B4002(-) granulocytes. The percentages of B4002(-) granulocytes in 
two patients (Cases 16 [A] and 20 [B]) were determined several times after ATG/CsA therapy. Both 
patients responded to the therapy and their hematological recovery was associated with a decrease in the 
B4002(-) granulocyte percentage. 
 
Figure 5. Deduced mechanisms responsible for the escape of HSPCs from cytotoxic T cells specific 
for auto-antigens presented by HLA-B4002. Normal HSPCs are killed by CTLs that recognize 
auto-antigens presented by HLA-B4002 (A), but HSPCs that have undergone various mutations of 
HLA-B4002 escape this CTL attack in different ways, such as via the complete loss of HLA-B4002 
expression due to 6pLOH, nonsense and frameshift mutations, or deactivation of splice sites (B), partial 
loss of HLA-B4002 protein due to alternative splice site formation (C), and failure of CD8+ T cell binding 
to the α-3 domain of HLA-B4002 (D) 
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